SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Tuesday reported a loss of $59.7 million in its fourth quarter.
The San Francisco-based company said it had a loss of 32 cents per share.
The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.
The biopharmaceutical company posted revenue of $22 million in the period, also surpassing Street forecasts. Seven analysts surveyed by Zacks expected $21.9 million.
For the year, the company reported that its loss narrowed to $368.2 million, or $1.97 per share. Revenue was reported as $92.1 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR
Copyright © 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.